| Literature DB >> 21784540 |
Zoltán Papp1, István Édes, Sonja Fruhwald, Stefan G De Hert, Markku Salmenperä, Heli Leppikangas, Alexandre Mebazaa, Giovanni Landoni, Elena Grossini, Philippe Caimmi, Andrea Morelli, Fabio Guarracino, Robert H G Schwinger, Sven Meyer, Lars Algotsson, Bernt Gerhard Wikström, Kirsten Jörgensen, Gerasimos Filippatos, John T Parissis, Martín J García González, Alexander Parkhomenko, Mehmet Birhan Yilmaz, Matti Kivikko, Piero Pollesello, Ferenc Follath.
Abstract
The molecular background of the Ca(2+)-sensitizing effect of levosimendan relates to its specific interaction with the Ca(2+)-sensor troponin C molecule in the cardiac myofilaments. Over the years, significant preclinical and clinical evidence has accumulated and revealed a variety of beneficial pleiotropic effects of levosimendan and of its long-lived metabolite, OR-1896. First of all, activation of ATP-sensitive sarcolemmal K(+) channels of smooth muscle cells appears as a powerful vasodilator mechanism. Additionally, activation of ATP-sensitive K(+) channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection. Finally, it has become evident, that levosimendan possesses an isoform-selective phosphodiesterase-inhibitory effect. Interpretation of the complex mechanism of levosimendan action requires that all potential pharmacological interactions are analyzed carefully in the framework of the currently available evidence. These data indicate that the cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21784540 DOI: 10.1016/j.ijcard.2011.07.022
Source DB: PubMed Journal: Int J Cardiol ISSN: 0167-5273 Impact factor: 4.164